Introduction/Background Uterine leiomyosarcomas (LMS) are rare, aggressive gynecological malignancies of the female reproductive tract. .One of the challenging directions in advancing the prognosis and optimization of treatment tactics in LMS is investigating the expression of molecular-biological markers in tumor tissue. So, the aim of our study was to evaluate the expression of p53, Bcl-2, Bax and Ki-67 and their prognostic relevance.

Methodology a retrospective chart review was done to 198 patients with LMS from 1971 to 2021. Immunohistochemical (IHC) staining for 20 patients was performed for p53, Bcl-2, Bax and Ki-67. Negative and positive IHC staining was scored for each marker. Survival was determined from the time of initial diagnosis to last follow-up.

Results ten (50%) patients with LMS expressed p53. P53+ patients mostly had multiple metastases, compared to p53– patients with solitar metastases (60% against 20%) (p<0,05). Eleven (55%) patients expressed Bcl-2 and 4 (20%) expressed Bax. In Bcl-2 + patients distant metastases were observed in 45,5%, compared to Bcl-2 – patients were, were we observed metastatic disease in 77,8% (p=0,068). Expression of ki-67 was observed in 15 patients (75%).

Conclusion LMS patients with p53 expression had a poorer survival compared to LMS patients with negative expression (p53+ — 26,7±18,4% and p53– — 80,0±12,6%) (p<0,05). On opposite, the disease-free survivla is better in bcl-2+ patients, compared to patients, who don’t express bcl-2 (47,2±19,6% and 28,1±18,0%, respectevly (p>0,05). We didn’t observe statistical significant difference in survival depending on Bax expression. LMS patients with Ki-67 expression had a poorer survival compared to LMS patients with negative expression (34,9±13,1% and 60,0±20,7%, respectively (p>0,05). Our study indicates that p53 expression may serve as a prognostic marker for LMS patients.

Disclosures No Disclosures